The effects of beraprost sodium on treatment and prevention of complications in patients undergoing maintenance hemodialysis with arteriovenous grafts

Abstract

Objective To evaluate the safety and efficacy of beraprost sodium on treatment and prevention of complications in patients undergoing maintance hemodialysis with arteriovenous grafts. Methods 25 patients undergoing maintance hemodialysis with 26 cases of arteriovenous grafts in Jiangmen Central Hospital from May 2014 to May 2016 were enrolled in this study, and they were divided into observation group and control group randomly according to digital method. The patients in the observation group were treated with beraprost sodium(40 μg/time, three times daily), and the patients in the control group were treated with aspirin (100 mg daily). All the patients were followed up for 24 months until the obstruction of arteriovenous grafts occurred or withdrawed from dialysis. Results The estimation and comparison of median survival time was no statistically significance between the observation group and the control groups (P>0.05). It was emphasized that thrombosis and serious vascular stenosis occurred in 18 months after operation.4 cases of thrombosis and 6 cases of serious vascular stenosis were observed in the control group, as compared with 2 cases of thrombosis and 4 cases of serious vascular stenosis in the observation group up to 24 months after operation(P>0.05). There were no statistical significant differences. There were no major bleedings in both groups. Conclusion Our data indicated that the beraprost sodium tablet was safe for the prevention of arteriovenous grafts dysfunction in maintance hemodialysis patients, but was not sufficiently effective. Key words: Maintance hemodialysis; Beraprost sodium; Arteriovenous fistula; Grafts